{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:31:49Z","timestamp":1789637509334,"version":"4.0.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Understanding the detailed symptom spectrum of chemotherapy-induced peripheral neuropathy (CIPN) could facilitate shared decision-making and promote early intervention.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the symptom spectrum of patient-reported CIPN associated with nab-paclitaxel, paclitaxel, and docetaxel treatments among patients with breast cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective cohort study was conducted at 9 medical centers across China from 2019 to 2021. Participants included hospitalized women diagnosed with invasive breast cancer, assessed with overlap propensity score weighting. Data were analyzed from from December 2021 to May 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Treatment with nab-paclitaxel\u2013, paclitaxel-, or docetaxel-based regimens.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Patient-reported CIPN on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire: CIPN 20-item instruments, consisting of sensory, motor, and autonomic scales. Multiple regression models were adjusted for baseline patient, tumor, and treatment characteristics.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 1234 participants, the mean (SD) age was 50.9 (10.4) years, and 295 patients (23.9%) received nab-paclitaxel, 514 patients (41.7%) received paclitaxel, and 425 patients (34.4%) received docetaxel. The nab-paclitaxel group mostly reported numbness in hands or feet related to sensory symptoms (83 patients [81.4%]), while the paclitaxel and docetaxel groups reported mainly motor (eg, weakness in legs: 60 patients [47.2%] in the paclitaxel group; 52 patients [44.4%] in the docetaxel group) and autonomic (eg, blurred vision: 58 patients [45.7%] in the paclitaxel group; 51 patients [43.6%] in the docetaxel group) symptoms. Patients reported motor symptoms earlier than sensory abnormalities, with a median of 0.4 (95% CI, 0.4-2.3) weeks in the nab-paclitaxel group, 2.7 (95% CI, 1.7-3.4) weeks in the paclitaxel group, and 5.6 (95% CI, 3.1-6.1) weeks in the docetaxel group. After overlap propensity score weighting and compared with the nab-paclitaxel group, the risks of patient-reported CIPN were lower in the paclitaxel (hazard ratio [HR], 0.59 [95% CI, 0.41-0.87]; P<\/jats:italic>\u2009=\u2009.008) and the docetaxel (HR, 0.65 [95% CI, 0.45-0.94]; P<\/jats:italic>\u2009=\u2009.02) groups. Similarly, patients who received paclitaxel (HR, 0.44 [95% CI, 0.30-0.64]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) or docetaxel (HR, 0.52 [95% CI, 0.36-0.75]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) reported less sensory discomfort compared with those who received nab-paclitaxel. However, the risk of patients in the paclitaxel or docetaxel groups reporting motor (paclitaxel: HR, 0.76 [95% CI, 0.52-1.11]; P<\/jats:italic>\u2009=\u2009.15; docetaxel: HR, 0.69 [95% CI, 0.47-1.01]; P<\/jats:italic>\u2009=\u2009.05) and\/or autonomic (paclitaxel: HR, 1.00 [95% CI, 0.68-1.49]; P<\/jats:italic>\u2009=\u2009.98; docetaxel: HR, 0.88 [95% CI, 0.59-1.30]; P<\/jats:italic>\u2009=\u2009.52) symptoms was not lower than that in the nab-paclitaxel group.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of women with invasive breast cancer, nab-paclitaxel was associated with more severe CIPN than either paclitaxel or docetaxel. In addition to sensory symptoms, the risk of motor and autonomic abnormalities was not low among these 3 taxanes, and patients-reported motor symptoms even earlier than sensory symptoms. These findings may facilitate early detection and intervention for CIPN in taxane treatments for breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.39788","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T15:01:26Z","timestamp":1667401286000},"page":"e2239788","source":"Crossref","is-referenced-by-count":51,"title":["Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Hongnan","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Peking University Clinical Research Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuee","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital of HuanXing ChaoYang District, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lv","sequence":"additional","affiliation":[{"name":"Cancer Center, First Affiliated Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[{"name":"Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"3","key":"zoi221125r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi221125r2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"zoi221125r3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"11","key":"zoi221125r4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jama.2021.7458","article-title":"Recommendations for prevention and management of chemotherapy-induced peripheral neuropathy.","volume":"326","author":"Derman","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"zoi221125r5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up.","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi221125r6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi221125r7","first-page":"530","article-title":"Agreement between patient-reported symptoms and their documentation in the medical record.","volume":"14","author":"Pakhomov","year":"2008","journal-title":"Am J Manag Care"},{"issue":"2","key":"zoi221125r8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"zoi221125r9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi221125r10","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1002\/cncr.27489","article-title":"Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.","volume":"118","author":"Reeves","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"zoi221125r11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30.","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi221125r12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer\u2014the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial.","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"issue":"16","key":"zoi221125r13","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer.","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"issue":"1 Spec. No.","key":"zoi221125r14","first-page":"SP37","article-title":"Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel\/nab-paclitaxel.","volume":"27","author":"Brady","year":"2021","journal-title":"Am J Manag Care"},{"issue":"11","key":"zoi221125r15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","article-title":"Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J Clin Oncol"},{"key":"zoi221125r16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2020.02.011","article-title":"Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: a pilot study.","volume":"51","author":"Salgado","year":"2020","journal-title":"Breast"},{"issue":"5","key":"zoi221125r17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/onco.13697","article-title":"Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response.","volume":"26","author":"Timmins","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"zoi221125r18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi221125r19","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2013Neurotoxicity (FACT\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"zoi221125r20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/10618600.2016.1208616","article-title":"An efficient implementation of the EMICM algorithm for the interval censored NPMLE.","volume":"26","author":"Anderson-Bergman","year":"2017","journal-title":"J Comput Graph Stat"},{"issue":"4","key":"zoi221125r22","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1214\/19-AOAS1282","article-title":"Propensity score weighting for causal inference with multiple treatments.","volume":"13","author":"Li","year":"2019","journal-title":"Ann Appl Stat"},{"issue":"19","key":"zoi221125r23","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models.","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"2","key":"zoi221125r24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MLR.0b013e3181c1328f","article-title":"The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health.","volume":"48","author":"Spreeuwenberg","year":"2010","journal-title":"Med Care"},{"issue":"9","key":"zoi221125r25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11910-016-0686-x","article-title":"Chemotherapy-related neurotoxicity.","volume":"16","author":"Taillibert","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"zoi221125r26","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1212\/WNL.48.5.1234","article-title":"Steroid myopathy in cancer patients.","volume":"48","author":"Batchelor","year":"1997","journal-title":"Neurology"},{"issue":"23","key":"zoi221125r27","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer.","volume":"363","author":"Mart\u00edn","year":"2010","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi221125r28","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi221125r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy.","volume":"4","author":"Mizrahi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi221125r30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2019.04.023","article-title":"Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program\u2013sponsored phase I trials.","volume":"115","author":"Kishimoto","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"zoi221125r31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"zoi221125r32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","article-title":"Patient-reported outcomes from the phase III IMPASSION130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.","volume":"31","author":"Adams","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi221125r33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi221125r34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","article-title":"Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.","volume":"16","author":"Bernhard","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi221125r35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamaoncol.2022.0114","article-title":"Identifying patients whose symptoms are underrecognized during treatment with breast radiotherapy.","volume":"8","author":"Jagsi","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi221125r36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol"},{"key":"zoi221125r21","doi-asserted-by":"crossref","DOI":"10.1201\/9781315116945","volume-title":"Survival Analysis with Interval-Censored Data: A Practical Approach with Examples in R, SAS, and BUGS","author":"Bogaerts","year":"2017"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798100\/mo_2022_oi_221125_1666786669.40446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T15:01:35Z","timestamp":1667401295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.39788","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}